Document is current
Any future updates will be listed below
-
Authors
Yamamoto, Takaya
Tsukita, Yoko
Katagiri, Yu
Matsushita, Haruo
Umezawa, Rei
Ishikawa, Yojiro
Takahashi, Noriyoshi
Suzuki, Yu
Takeda, Kazuya
Miyauchi, Eisaku
Saito, Ryota
Katsuta, Yoshiyuki
Kadoya, Noriyuki
Jingu, Keiichi
- License Information
-
More Information
Article History
Received: 7 January 2022
Accepted: 2 March 2022
First Online: 4 April 2022
Declarations
:
: This study was approved by the Tohoku University Research Ethics Committee (reference number: 2021–1-460). Written informed consent was waived due to the study design by the Tohoku University Research Ethics Committee. However, all patients were offered the chance to opt-out of participation in this study by provinding information about this study via the internet. Lack of opt-out consent was obtained from all patients. The study was carried out in accordance with the Declaration of Helsinki.
: Not applicable.
: TY, YT, YK<sup>1</sup> and RS have received lecturer fees from AstraZeneca KK.EM has received grants from Chugai Pharmaceutical Co Ltd. and Eli Lily Japan KK., honouraria from AstraZeneca KK., Taiho Pharmaceutical Co Ltd., Daiichi Sankyo KK., Boehringer Ingelheim Japan Inc., Bristol Myers Squibb Co Ltd., Novartis Pharma KK., MSD KK., Kyowa Kirin Co Ltd., Merck Biopharma Co Ltd., Pfizer Inc., Ono Pharmaceutical Co Ltd., Otsuka Pharmaceutical Co Ltd. and Towa Pharmaceutical Co. Ltd., and EM has been an advisory board of Chugai Pharmaceutical Co Ltd, Boehringer Ingelheim Japan Inc and Eli Lilly Japan KK. KJ has received consulting fees from Varian Medical Systems and Elekta, and honouraria from Shimazu. Co. HM, RU, YI, NT, YS, YK<sup>2</sup> and NK have no conflicts of interest.
